bioAffinity Technologies, Inc. BIAFW
0.17 USD -0.05 (-24.31%)
Nov 10, 2026, 10:28 AM EST
0.15065 Day range 0.165
0.15065 52-week range 0.165
- YTD
- +9.53%
- 1 year
- +9.53%
- Market cap
- 5.36M
- Revenue (ttm)
- 7.32M
- Profit margin
- -119.41%
- YTD return
- +9.53%
- 1-year return
- +9.53%
- Volume
- 403
- Open
- 0.47
- Previous close
- 0.218
- Day's range
- 0.15065 – 0.165
- 52-week range
- 0.15065 – 0.165
- Beta
- 3.12
No chart data for this range yet.
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.65
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 12047.40%
- Free cash flow
- -4.29M
- Total cash
- 801.31K
- Total debt
- 1.38M
- Return on equity
- -151.52%
- Short % of float
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Next earnings
Consensus EPS estimate 0.00.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- bioaffinitytech.com
News
Your note
Sign in to keep a note on BIAFW — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 15.88% | 204,082 | 68.65K | Sep 29, 2024 |
| Clear Street LLC | 4.27% | 54,933 | 18.48K | Sep 29, 2024 |
| Citadel Advisors Llc | 3.05% | 39,180 | 13.18K | Sep 29, 2024 |
| UBS Group AG | 0.04% | 467 | 157 | Sep 29, 2024 |